Hydrocodone is generally considered slightly weaker than morphine on a milligram-for-milligram basis. When cancer patients are switched from hydrocodone to morphine, the typical conversion ratio is about 1.5 to 1, meaning it takes roughly 1.5 mg of hydrocodone to match the pain relief of 1 mg of oral morphine. But “stronger” is a surprisingly slippery concept when applied to opioids, because how your body metabolizes each drug, what other medications are mixed in, and even your individual genetics can shift the real-world comparison considerably.
What the Conversion Ratios Actually Show
The most commonly cited way to compare opioid strength is through equianalgesic dosing, which asks how many milligrams of one drug produce roughly the same pain relief as a set dose of another. In a study of 100 cancer patients being rotated from hydrocodone to other opioids, the median conversion ratio from hydrocodone to morphine was 1.5. That means clinicians needed about 50% more hydrocodone than morphine to achieve equivalent relief.1PubMed Central. The opioid rotation ratio of hydrocodone to strong opioids in cancer patients By that measure, morphine is the more potent drug.
An important wrinkle in that same data: the conversion ratio was not fixed. Patients taking higher doses of hydrocodone (40 mg per day or more) actually needed relatively less morphine to replace it, meaning the potency gap shrank at higher doses.2The Oncologist. The Opioid Rotation Ratio of Hydrocodone to Strong Opioids in Cancer Patients This is a common pattern in opioid pharmacology, where simple conversion charts work reasonably well at low doses but become less reliable as doses climb.
A separate controlled study in recreational opioid users, which compared intravenous hydrocodone, morphine, and oxycodone head-to-head, arrived at a consistent conclusion: the potency ranking was oxycodone first, then morphine, then hydrocodone.3PubMed Central. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies While all three produced similar types of effects at equivalent doses, hydrocodone required the highest milligram dose to match the other two.
Similar Receptors, Different Pathways
If hydrocodone and morphine both work by activating the same receptor in the brain, why does one require a higher dose? Part of the answer lies in how tightly each molecule grabs onto that receptor. A ranking study that measured binding strength for a range of opioids placed both hydrocodone and morphine in the same middle tier, with binding constants between 1 and 100 nanomolar.4PubMed. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs They are in the same neighborhood, not in different leagues. The drugs that sit in the highest-potency tier, with binding constants below 1 nanomolar, include hydromorphone and oxymorphone, both of which are several times stronger than either morphine or hydrocodone.
So the receptor-level picture suggests these two drugs are closer in strength than the 1.5-to-1 conversion ratio implies. The bigger story is what happens after each drug enters your bloodstream, because hydrocodone and morphine are broken down by completely different enzyme systems, producing different metabolites that alter the overall pain-relieving effect.
Hydrocodone as a Pro-Drug
One of the more interesting findings in recent years is that hydrocodone may work partly, or even mostly, through a metabolite rather than through the parent drug itself. Your liver converts a portion of hydrocodone into hydromorphone, which is a far more potent opioid. A study of postoperative patients found that it was the hydromorphone levels in their blood, not the hydrocodone levels, that correlated with actual pain relief.5PubMed. Hydrocodone in postoperative personalized pain management: pro-drug or drug?
This conversion is handled by the liver enzyme CYP2D6, and people vary enormously in how active that enzyme is. In that same study, about 60% of participants were normal metabolizers, 30% were intermediate, 3% were poor metabolizers who barely converted hydrocodone at all, and 7% were ultra-rapid metabolizers who converted it very efficiently. The poor metabolizers had hydromorphone blood levels roughly eight times lower than the ultra-rapid group.5PubMed. Hydrocodone in postoperative personalized pain management: pro-drug or drug? In plain terms, a dose of hydrocodone that works well for one person might barely touch another person’s pain, depending on their genetic makeup.
Clinical guidelines have acknowledged this variability but stopped short of making strong prescribing recommendations based on CYP2D6 testing for hydrocodone, largely because the evidence base is still thin compared to drugs like codeine and tramadol, where the genetic link is better established.6PubMed Central. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
Morphine’s Metabolites Cut Both Ways
Morphine has its own metabolic complexity, though the enzymes involved are different. The liver converts morphine primarily into two compounds. One, morphine-6-glucuronide, is itself a potent painkiller, sometimes more potent than morphine itself. The other, morphine-3-glucuronide, does something counterproductive: in animal studies, it causes increased sensitivity to pain and can actually reduce the analgesic effect of morphine when both are present.7PubMed Central. Morphine-3-Glucuronide, Physiology and Behavior
This dual-metabolite situation means morphine’s effective potency can vary depending on how your body balances the production of these two compounds. It also creates a specific problem for people with impaired kidney function, because both metabolites are cleared through the kidneys. When they accumulate, the risk of toxicity rises. A review of opioid use in older adults with chronic kidney disease flagged morphine as a drug that should not be used in patients with significant kidney impairment, precisely because its metabolites build up and become dangerous.8PubMed Central. Opioid Management in Older Adults with Chronic Kidney Disease: A Review Hydrocodone, while still metabolized by the liver and cleared by the kidneys, was not placed in the same restricted category, making it a potentially safer choice in that specific population.
Head-to-Head in Acute Pain
The potency question gets even messier when you look at real-world pain studies, because hydrocodone almost never comes alone. In the United States, it is overwhelmingly prescribed in combination with acetaminophen (the active ingredient in Tylenol), and that combination changes the comparison. A randomized trial in emergency department patients with acute arm or leg pain compared four single-dose treatments: ibuprofen plus acetaminophen, oxycodone plus acetaminophen, hydrocodone plus acetaminophen, and codeine plus acetaminophen. Two hours after dosing, none of the four groups showed a statistically significant difference in pain reduction from any of the others.9JAMA. Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial
That result surprised a lot of people, partly because it showed the ibuprofen-and-acetaminophen group doing just as well as any of the opioid groups, and partly because hydrocodone-plus-acetaminophen performed in the same range as oxycodone-plus-acetaminophen despite oxycodone being considered the stronger opioid. The acetaminophen component contributed meaningful pain relief on its own, and research into that combination has confirmed the two drugs work through different mechanisms, producing an additive effect.10PubMed Central. Methodological considerations in the evaluation of analgesic combinations: acetaminophen (paracetamol) and hydrocodone in postpartum pain When you take a hydrocodone-acetaminophen tablet, you are not just getting hydrocodone. You are getting two painkillers working through separate pathways, which muddies the comparison with morphine taken alone.
Do Side Effects Differ?
Given that hydrocodone and morphine activate the same receptor, it is not surprising that their side-effect profiles overlap heavily. Constipation is the most common complaint with any opioid, and a clinical guideline on opioid-induced constipation found no difference in rates between morphine, hydrocodone, and hydromorphone.11Oxford Academic (Pain Medicine). Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline Nausea, drowsiness, and itching are similarly common with both drugs.
One area where there may be a divergence involves a phenomenon called opioid-induced hyperalgesia, where the pain medication paradoxically increases pain sensitivity over time. An animal study of burn injury found that morphine produced significant hyperalgesia in control animals, while hydrocodone produced only minimal hyperalgesia under the same conditions.12Pain Medicine. Hydrocodone is More Effective than Morphine or Oxycodone in Suppressing the Development of Burn-Induced Mechanical Allodynia This is an animal finding and has not been firmly replicated in human clinical trials, but it is intriguing because it aligns with what we know about morphine’s problematic metabolite M3G, which has been shown to provoke heightened pain sensitivity in rodents.
Abuse Potential and Subjective Effects
People often assume that a “stronger” opioid is automatically more addictive, but the evidence for hydrocodone versus morphine does not support that idea. A review of abuse liability data found no consistent, clinically significant difference in abuse potential between the two drugs.13PubMed Central. Likeability and Abuse Liability of Commonly Prescribed Opioids In the controlled intravenous study mentioned earlier, both drugs produced similar “liking” ratings at equivalent doses, with the effects being qualitatively similar across all three opioids tested.3PubMed Central. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies
The risk of dependence and addiction with any opioid has far more to do with dose, duration of use, and individual vulnerability than with which specific opioid is prescribed. A patient taking hydrocodone for two weeks after surgery and a patient taking morphine for two weeks face broadly similar risks.
Why Hydrocodone Was Rescheduled
Until October 2014, hydrocodone combination products (like Vicodin) were classified as Schedule III controlled substances in the United States, while morphine sat in the more restrictive Schedule II. That scheduling gap meant hydrocodone was far easier to prescribe: doctors could phone in refills, patients could get multiple refills on a single prescription, and the overall regulatory friction was lower. The result was that hydrocodone became the most commonly prescribed opioid in the country by a wide margin.
When the DEA moved hydrocodone combination products to Schedule II, prescribing dropped substantially. One state-level study in Ohio found prescriptions fell by nearly 6% immediately and continued declining at about 0.8% per month afterward.14PubMed Central. Effects of Rescheduling Hydrocodone on Opioid Prescribing in Ohio Nationally, quarterly hydrocodone dispensing dropped by about 177 million dosage units in the period right after rescheduling.15PubMed Central. The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths
The unintended consequence was substitution. A systematic review of 24 studies found that while hydrocodone prescribing fell across the board, prescribing of tramadol, codeine-containing products, and oxycodone-containing products all increased, with some studies reporting codeine prescription jumps of over 1,000%.16Journal of the American Pharmacists Association. Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review In some cases, the substitutes carried their own risks: codeine has the same CYP2D6 variability problem as hydrocodone, and tramadol carries seizure risk. The net effect on overall opioid-related harm has been mixed, with some studies showing a drop in total morphine-equivalent dispensing and others showing no change or even an increase.
When a Clinician Might Choose One Over the Other
If the two drugs have similar side effects and similar abuse potential, and the potency difference is modest, why would a doctor pick one over the other? Several practical factors come into play.
Kidney function is one of the clearest differentiators. As noted earlier, morphine’s active metabolites accumulate dangerously in patients with poor kidney function, making it a drug to avoid in that population.8PubMed Central. Opioid Management in Older Adults with Chronic Kidney Disease: A Review Hydrocodone, while still requiring caution, does not carry the same specific warning for non-dialysis kidney disease patients.
The availability of combination formulations is another factor. For mild to moderate pain where an opioid is judged necessary, the built-in acetaminophen in most hydrocodone products provides additional pain relief through a non-opioid mechanism, potentially allowing a lower opioid dose overall. Morphine, by contrast, is typically prescribed as a standalone drug and is more commonly used for moderate to severe pain or in situations where around-the-clock dosing with extended-release formulations is needed.
Genetic testing is not yet routine in most clinical settings, but a patient who has previously had poor results with hydrocodone (or with codeine, which uses the same metabolic pathway) might do better on morphine, whose effectiveness does not depend on CYP2D6 activity. Conversely, a patient with kidney concerns might be steered away from morphine toward hydrocodone or another alternative.
An Animal Finding Worth Watching
The burn-injury animal study mentioned earlier turned up something unexpected beyond the hyperalgesia difference. Hydrocodone was more effective than either morphine or oxycodone at suppressing the development of mechanical allodynia, a type of pain where normally non-painful sensations like light touch become painful.12Pain Medicine. Hydrocodone is More Effective than Morphine or Oxycodone in Suppressing the Development of Burn-Induced Mechanical Allodynia This is a single preclinical result, so it would be premature to draw clinical conclusions from it. But it hints that the question of which opioid is “stronger” depends heavily on what kind of pain you are measuring. A drug that looks weaker in a standard acute-pain comparison might perform differently in models of nerve-related or injury-related pain sensitization. If this finding holds up in human research, it could reshape how clinicians think about opioid selection for burn patients or others at risk for central pain sensitization.